+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Leukemia Research 36(9): 1112-1118

Forty-seven percent of adults with acute myeloid leukemia (AML) who entered the ALFA-982 trial and achieved a first complete remission (CR) experienced a first relapse. We examined the outcome of these 19 adult patients. Eighty-four patients (44%) achieved a second CR. The median overall survival (OS) after relapse was 8.9months with a 2-year OS at 25%. Factors predicting a better outcome after relapse were stem cell transplant (SCT) performed in second CR and a first CR duration >1year. Risk groups defined at the time of diagnosis and treatment received in first CR also influenced the outcome after relapse. The best results were obtained in patients with core binding factor (CBF)-AML, while patients initially defined as favorable intermediate risk showed a similar outcome after relapse than those initially entering the poor risk group. We conclude that most adult patients with recurring AML could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option at this stage of the disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 054809495

Download citation: RISBibTeXText

PMID: 22647869

DOI: 10.1016/j.leukres.2012.04.020

Related references

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21(9): 1907-1914, 2007

Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 21(3): 453-461, 2007

Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leukemia and Lymphoma 53(6): 1068-1076, 2012

Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. Yearbook of Oncology 2006: 174-175, 2006

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Journal of Clinical Oncology 23(3): 482-493, 2004

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. Journal of Clinical Oncology 32(3): 219-228, 2014

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia. European Journal of Haematology 98(5): 443-449, 2017

Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia. Journal of Clinical Oncology 33(18): 2072-2083, 2015

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 118(7): 1754-1762, 2011

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109(12): 5129-5135, 2007

Treatment of acute myeloid leukemia younger adults: the GOELAM experience. Annals of Hematology 83 Suppl 1: S104-S105, 2004

Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype. Haematologica 2018, 2018

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Journal of Clinical Oncology 25(31): 4938-4945, 2007

Final Report of the Effect of Cytogenetic Risk Group on Outcome of Patients with Acute Myeloid Leukemia in First Relapse Treated with Gemtuzumab Ozogamicin. Blood 100(11): Abstract No 740, November 16, 2002

A case of acute myeloid leukemia initially treated as chronic lymphocytic leukemia: what do we know about t(4;12)(q12;p13)?. Cancer Genetics and Cytogenetics 203(2): 348-351, 2011